Slingshot members are tracking this event:

Ignyta (RXDX) Presents Phase 1 Data Evaluating Entrectinib in Patients with TRK-, ROS1- or ALK-Positive Solid Tumors

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 09, 2017
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 1, Entrectinib, Trk-, Ros1-, Alk-positive, Solid Tumors